Literature DB >> 7659284

beta-Amyloid peptides enhance binding of the calcium mobilising second messengers, inositol(1,4,5)trisphosphate and inositol-(1,3,4,5)tetrakisphosphate to their receptor sites in rat cortical membranes.

R F Cowburn1, B Wiehager, E Sundström.   

Abstract

We studied the effects of the beta-amyloid (A beta) peptides A beta-(1-40), A beta-(25-35-NH2) and A beta-(25-35-COOH) on binding of the phosphoinositide derived, calcium mobilising, second messengers inositol(1,4,5)-trisphosphate (Ins(1,4,5)P3) and inositol(1,3,4,5)-tetrakisphosphate (Ins(1,3,4,5)P4) to their receptor sites in rat cerebral cortical membranes. All three peptides gave statistically significant dose-dependent increases in both [3H]Ins(1,4,5)P3 and [3H]Ins(1,3,4,5)P4 binding. A beta-(1-40) and A beta-(25-35-NH2) enhanced [3H]Ins(1,4,5)P3 and [3H]Ins(1,3,4,5)P4 binding to a similar extent. In comparison, A beta-(25-35-COOH) gave much greater enhancements of [3H]Ins(1,4,5)P3 and [3H]Ins(1,3,4,5)P4 binding. However, a component of the latter appeared to be due to the formation of pelletable A beta-(25-35-COOH)/[3H]Ins(1,3,4,5)P4 aggregates, that occurred in the absence of membranes. These results raise the possibility that A beta affects calcium homeostasis by a direct action on [3H]Ins(1,4,5)P3 and [3H]Ins(1,3,4,5)P4 receptor sites.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7659284     DOI: 10.1016/0304-3940(94)11549-3

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  4 in total

1.  Comparative studies on [Ca2+]i-level of fibroblasts from Alzheimer patients and control individuals.

Authors:  A Palotás; J Kálmán; G Laskay; A Juhász; Z Janka; B Penke
Journal:  Neurochem Res       Date:  2001-07       Impact factor: 3.996

2.  Effects of beta-amyloid-(25-35) peptides on radioligand binding to excitatory amino acid receptors and voltage-dependent calcium channels: evidence for a selective affinity for the glutamate and glycine recognition sites of the NMDA receptor.

Authors:  R F Cowburn; B Wiehager; E Trief; M Li-Li; E Sundström
Journal:  Neurochem Res       Date:  1997-12       Impact factor: 3.996

3.  Whole blood samples from Alzheimer patients and control donors demonstrate fluorimetric differences.

Authors:  András Palotás; János Kálmán; Miklós Palotás; Keyvan Matin; Károly Szentpáli; Attila Paszt; Zoltán Janka; Botond Penke
Journal:  Neurochem Res       Date:  2002-12       Impact factor: 3.996

Review 4.  Hyperactivity Induced by Soluble Amyloid-β Oligomers in the Early Stages of Alzheimer's Disease.

Authors:  Audrey Hector; Jonathan Brouillette
Journal:  Front Mol Neurosci       Date:  2021-01-07       Impact factor: 5.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.